Tocilizumab (TCZ) is a humanized monoclonal antibody against the interleukin-6 receptor (IL-6R), which was first approved for the treatment of rheumatoid arthritis (RA) [2]. This evidence concerns the gene IL6R and rheumatoid arthritis.